Therapy Detail

Therapy Name WANT3
Synonym
Therapy Description

WANT3 is a peptide that targets NCKAP1 thereby disrupting the interaction between NCKAP1 and WASF3, and may result in suppression of cell invasion (PMID: 27432794).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
WANT3 WANT3 is a peptide that targets NCKAP1 thereby disrupting the interaction between NCKAP1 and WASF3, and may result in suppression of cell invasion (PMID: 27432794).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown prostate cancer not applicable WANT3 Preclinical - Cell culture Actionable In a preclinical study, WANT3 treatment resulted in suppression of cell invasion of prostate cancer cells in culture (PMID: 27432794). 27432794
Unknown unknown colon cancer not applicable WANT3 Preclinical - Cell culture Actionable In a preclinical study, WANT3 treatment resulted in suppression of cell invasion of colon cancer cells in culture (PMID: 27432794). 27432794
Unknown unknown breast cancer not applicable WANT3 Preclinical - Cell culture Actionable In a preclinical study, WANT3 treatment resulted in suppression of cell invasion of breast cancer cells in culture (PMID: 27432794). 27432794
Clinical Trial Phase Therapies Title Recruitment Status